Celgene Corp (CELG) 88.37 $CELG
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Midday Glance: Biotechnology companies
AP - Mon Jul 14, 12:29PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Early Glance: Biotechnology companies
AP - Mon Jul 14, 9:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Are These the Best Big Biotech Stocks for Your Portfolio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 4:00PM CDT
Gilead Sciences has had a banner year. Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations. Celgene has had a more mixed experience this year,...
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Celgene Up 17.1% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Thu Jul 10, 9:55AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 2 months, Celgene has returned 17.08% as of today's recent price of $86.56.
Celgene Gets Bad News, Shares Climb Anyway
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 7:46AM CDT
Otezla, one of the big potential blockbuster drugs Celgene is depending on to expand its revenue generation beyond Revlimid, failed a phase 3 trial in ankylosing spondylitis. And yet, at the end of the first full market day after announcing the...
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
'Fast Money' Recap: Digging Into Oil Prices
at The Street - Thu Jul 10, 4:00AM CDT
The trading panel looked at whether WTI will go lower, how that will affect transportation stocks and how successful a Kim Kardashian mobile game app can be.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
Celgene's Otezla fails trial
at Investor's Business Daily - Wed Jul 09, 5:45PM CDT
Big-cap biotech Celgene (CELG) said that its new drug failed a trial for an inflammatory spinal disease, but the stock rebounded from a big drop early Wed. as analysts said the news wasn't a surprise. The phase 3 study looked at Otezla to treat...
Pluristem Initiates Trial in South Korea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 5:00PM CDT
Pluristem Therapeutics Inc. (PSTI) announced that it has initiated a phase II trial in South Korea to evaluate PLacental eXpanded cells for the treatment of intermittent claudication.
Celgene Drug Misses Mark in Spinal Arthritis Study
Ben Fidler, The Motley Fool - Motley Fool - Wed Jul 09, 1:00PM CDT
Celgene branched out from its blood cancer roots earlier this year when it won an FDA nod for an oral arthritis drug called apremilast (Otezla). But the Summit, NJ-based company's plan to turn that drug into a franchise took a hit on Wednesday...
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Midday Glance: Biotechnology companies
AP - Mon Jul 14, 12:29PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Early Glance: Biotechnology companies
AP - Mon Jul 14, 9:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Are These the Best Big Biotech Stocks for Your Portfolio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 4:00PM CDT
Gilead Sciences has had a banner year. Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations. Celgene has had a more mixed experience this year,...
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Celgene Up 17.1% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Thu Jul 10, 9:55AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 2 months, Celgene has returned 17.08% as of today's recent price of $86.56.
Celgene Gets Bad News, Shares Climb Anyway
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 7:46AM CDT
Otezla, one of the big potential blockbuster drugs Celgene is depending on to expand its revenue generation beyond Revlimid, failed a phase 3 trial in ankylosing spondylitis. And yet, at the end of the first full market day after announcing the...
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
'Fast Money' Recap: Digging Into Oil Prices
at The Street - Thu Jul 10, 4:00AM CDT
The trading panel looked at whether WTI will go lower, how that will affect transportation stocks and how successful a Kim Kardashian mobile game app can be.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
Celgene's Otezla fails trial
at Investor's Business Daily - Wed Jul 09, 5:45PM CDT
Big-cap biotech Celgene (CELG) said that its new drug failed a trial for an inflammatory spinal disease, but the stock rebounded from a big drop early Wed. as analysts said the news wasn't a surprise. The phase 3 study looked at Otezla to treat...
Pluristem Initiates Trial in South Korea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 5:00PM CDT
Pluristem Therapeutics Inc. (PSTI) announced that it has initiated a phase II trial in South Korea to evaluate PLacental eXpanded cells for the treatment of intermittent claudication.
Celgene Drug Misses Mark in Spinal Arthritis Study
Ben Fidler, The Motley Fool - Motley Fool - Wed Jul 09, 1:00PM CDT
Celgene branched out from its blood cancer roots earlier this year when it won an FDA nod for an oral arthritis drug called apremilast (Otezla). But the Summit, NJ-based company's plan to turn that drug into a franchise took a hit on Wednesday...
